For the more than 50 million Americans living with chronic pain, a new approach to relief is emerging from laboratories at the University of Pennsylvania and collaborating institutions. Researchers have developed a gene therapy that aims to “turn off” pain signals directly in the brain, offering a potential alternative to opioids and their well-documented risks of addiction and side effects. The findings, published in the journal Nature, represent a significant step toward a future where chronic pain management doesn’t automatically equate to a reliance on potentially dangerous narcotics.
Chronic pain, often described as debilitating and isolating, impacts nearly every aspect of life. It’s a condition that can feel relentless, like a constant, unyielding signal firing in the nervous system. While medications like morphine can temporarily reduce the intensity of that signal, they often come with a heavy cost. Opioids don’t just target pain centers; they affect other brain regions, leading to a range of adverse effects and a high potential for dependence. This new therapy, yet, seeks to address pain at its source with far greater precision.
A Targeted Approach to Pain Relief
The research team, comprised of scientists from the University of Pennsylvania Perelman School of Medicine and School of Nursing, Carnegie Mellon University, and Stanford University, focused on developing a gene therapy that mimics the pain-relieving effects of morphine, but without activating the brain’s reward pathways that contribute to addiction. The key, according to Gregory Corder, PhD, co-senior author and assistant professor of Psychiatry and Neuroscience at Penn, was to target the specific brain circuits involved in processing pain. “The goal was to reduce pain while lessening or eliminating the risk of addiction and dangerous side effects,” Corder said. “By targeting the precise brain circuits that morphine acts on, we believe this is a first step in offering new relief for people whose lives are upended by chronic pain.”
To achieve this level of precision, the researchers leveraged the power of artificial intelligence. They built an AI-powered system to study brain cells involved in tracking pain signals in mice. This system monitored natural behavior, estimated pain levels, and helped determine the optimal level of treatment needed. The insights gained from this AI analysis were then used to design the gene therapy itself.
How the Gene Therapy Works
The gene therapy introduces what researchers describe as a brain-specific “off switch” for pain. When activated, this switch reduces pain signals over a sustained period without interfering with normal sensations or triggering the addictive reward pathways. Essentially, it’s a targeted intervention that aims to quiet the pain signal without disrupting other crucial brain functions. “To our knowledge, this represents the world’s first CNS-targeted gene therapy for pain, and a concrete blueprint for non-addictive, circuit-specific pain medicine,” Corder explained.
The Urgency of Alternatives to Opioids
The development of this therapy comes at a critical time. The opioid crisis continues to devastate communities across the United States. According to the Centers for Disease Control and Prevention, over 107,000 people died from drug overdoses in the U.S. In 2022, with opioids being involved in the vast majority of those deaths. Even before the height of the crisis, the economic burden of chronic pain was substantial. The National Institutes of Health estimates that chronic pain affects approximately 50 million American adults and costs the nation more than $635 billion annually in medical treatment and lost productivity.
The require for safer, more effective pain management strategies is clear. A 2025 survey conducted by Pew Research Center found that nearly half of residents in Philadelphia knew someone with opioid utilize disorder, and one-third knew someone who had died from an overdose, highlighting the pervasive impact of the crisis on local communities.
From Lab to Clinic: Next Steps
The research team is now collaborating with Michael Platt, PhD, the James S. Riepe University Professor, Professor of Neuroscience, and Professor of Psychology, to advance the gene therapy toward potential clinical trials. Platt emphasized the long road ahead, stating, “The journey from discovery to implementation is long, and this represents a strong first step.” He added, speaking both as a scientist and as someone with personal experience with chronic pain within his family, “the potential to relieve suffering without fueling the opioid crisis is exciting.”
This research was supported by a six-year investigation funded by a National Institutes of Health New Innovator Award, which allowed the team to delve into the complexities of chronic pain development and persistence. The team has also filed a provisional patent application regarding the custom sequences used to develop the therapy (patent application number: 63/383,462 ‘Human and Murine Oprm1 Promoters and Uses Thereof’).
While the therapy is still in its early stages of development, the results offer a glimmer of hope for millions struggling with chronic pain. The next crucial step will be to assess the safety and efficacy of the gene therapy in human clinical trials, a process that could take several years. Researchers will be closely monitoring for any potential side effects and evaluating the long-term effectiveness of the treatment.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this promising research in the comments below, and share this article with anyone who might benefit from this information.
Related reading
